Health Care·NASDAQ·All covered stocks

BridgeBio Pharma Inc. (NASDAQ: BBIO) Stock News & Analysis

BridgeBio Pharma Inc. (NASDAQ: BBIO) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight tracks BBIO across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 3 articles published since April 30, 2026, providing investors with timely, data-driven analysis of BridgeBio Pharma Inc.'s financial performance and competitive position. New coverage is added each trading day.

Price

$84.02

Today

+1.31%

Mkt Cap

$16.5B

52W High

$93.42

52W Low

$42.09

Data via Finnhub · refreshes hourly · not financial advice

BBIO Coverage -- 3 Articles

Earnings Report·May 7, 2026

BridgeBio Pharma (NASDAQ: BBIO) Beats Revenue Guidance as Attruby Drives Growth

BridgeBio's Q1 revenue surge powered by Attruby sales beat estimates, though EPS missed—stock authorizes $500M buyback.

4 min readRead article

Important Legal Disclaimer

This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.

Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.

Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.